Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18284422 | 0.88 | NOTUM (0.58) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL3830811 | 0.86 | NOTUM (0.69) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL20043300 | 0.86 | NOTUM (0.51) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL12490655 | 0.84 | NOTUM (0.54) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL13440125 | 0.84 | NOTUM (0.56) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL5355256 | 0.83 | NOTUM (0.56) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL15077180 | 0.81 | NOTUM (0.53) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL3372362 | 0.81 | CA1 (0.65) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL8658786 | 0.81 | KDM4E (0.54) | NOTUMCA1CA2CA12CA7 | |
| SCHEMBL1367395 | 0.81 | NOTUM (0.47) | NOTUMCA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| US-9040712-B2 | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | NOTUM 4707/4885CA1 4785/4885CA2 3925/4885 |
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | NOTUM 3645/4885CA1 4810/4885CA2 4373/4885 |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | NOTUM 3645/4885CA1 4810/4885CA2 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.